TopAlliance Biosciences News and Activities

TopAlliance Biosciences is owned by Junshi Biosciences.

Junshi Biosciences is one of the...

• CSI 500;
• TOB Iconic 10,000.

Junshi Biosciences is a company listed under the stock ticker 688180 (HK).

View the org chart displaying its 11 main executives

Most searched biographies at TopAlliance Biosciences

• Sheng Yao, Chief Executive Officer and Executive Director
• Ning Li, Chairman of the Board
• Monica Hughes, Vice President of Project and Portfolio Management

Create your alert
to follow the executive moves at TopAlliance Biosciences.

Junshi Biosciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by TopAlliance Biosciences

• News Releases
• Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
• Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
• Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
• Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
• Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
• Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
• Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
• Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 | Eli Lilly and Company
• Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
• View more press releases Close

Social media about TopAlliance Biosciences

• TopAlliance Biosciences on Wikipedia, Google News & Yahoo Finance
• TopAlliance Biosciences on LinkedIn, X (Twitter) & YouTube